B2M and neoplasm: We conclude that in addition to genetic mutations leading to loss of B2M (e.g., Pat208), other non-genetic mechanisms also use by tumor cells (e.g., Pat99 and Pat25) and may lead to transient or long-term reduction in antigen presentation.